DoW Neurofibromatosis Investigator-Initiated Research Award

The Neurofibromatosis Investigator-Initiated Research Award is offered through the Department of Defense via the Defense Health Agency Contracting Activity as part of a broader military medical research portfolio focused on advancing treatments and understanding of complex diseases. The Neurofibromatosis Research Program is designed to support innovative and impactful scientific inquiry into neurofibromatosis, a group of genetic disorders that cause tumors to form on nerve tissue and can lead to significant health complications. This funding opportunity is positioned within federal efforts to accelerate biomedical discoveries that directly improve patient care and clinical outcomes for affected populations. The primary objective of this award is to fund high-impact research projects that address critical gaps in the understanding, diagnosis, or treatment of neurofibromatosis. The program encourages proposals across a wide spectrum of research phases, including basic, translational, and population-based studies, but explicitly excludes clinical trials. Applicants are expected to demonstrate a strong scientific rationale grounded in preliminary or published data relevant to neurofibromatosis. Research ideas may emerge from laboratory findings, clinical observations, epidemiological data, or other credible sources that support the feasibility and importance of the proposed work. Funding under this mechanism is structured into two distinct levels based on optional participation features. The first level supports applications that do not incorporate additional programmatic elements. The second level allows applicants to enhance their proposals through participation in either the Open Science Initiative or collaboration with a Qualified Collaborator. The Open Science Initiative promotes early data sharing and transparency within the neurofibromatosis research community, while the Qualified Collaborator option encourages interdisciplinary partnerships between basic scientists, clinicians, and biotechnology researchers. These features are intended to foster collaboration and accelerate the translation of findings into meaningful outcomes. Eligible applicants are broadly defined as unrestricted, allowing a wide range of entity types to apply, subject to any clarifications provided in the full announcement. This inclusivity supports participation from academic institutions, research organizations, private entities, and other qualified applicants capable of conducting rigorous scientific research. While no cost sharing or matching requirement is specified, applicants must ensure that their proposed budgets align with federal grant regulations and program expectations. Specific allowable costs and budget structures are typically detailed in the full funding announcement. The application process requires submission through established federal systems, and applicants must prepare comprehensive proposals that include detailed research plans, supporting data, and documentation demonstrating the relevance and feasibility of their work. While no pre-application requirement is specified in the provided summary, applicants are expected to adhere to all submission guidelines and deadlines. The current application cycle opened on June 25, 2026, and closes on September 22, 2026. Awards are anticipated following a competitive review process that evaluates scientific merit, impact, and alignment with program goals. Evaluation criteria generally emphasize the significance of the research question, the strength of preliminary data, the qualifications of the research team, and the potential for the project to advance the field of neurofibromatosis or improve patient care. Additional consideration may be given to proposals that incorporate collaborative or open science elements, particularly under the Level 2 funding structure. Applicants are encouraged to consult program resources and support channels, including the eBRAP Help Desk, for technical assistance during the application process. The program is not explicitly described as recurring, but similar Department of Defense research programs are often offered annually or periodically. The anticipated performance period, award amounts, and detailed evaluation timelines are typically outlined in the full announcement documentation. Applicants seeking further information or encountering technical issues may contact the eBRAP Help Desk via email or phone, ensuring access to support throughout the submission process.

Strong preliminary data and clear demonstration of high-impact potential are critical for competitiveness; aligning with optional collaboration or open science features may strengthen proposals